To read about OmniaBio’s initial funding support from the Government of Ontario, please visit our news page.
To read about OmniaBio’s private investor, read our news release here.
OmniaBio CEO, Mitchel Sivilotti, was recently profiled in Signals, read the feature here.
On September 20, 2022, Next Generation Manufacturing Canada (NGen) announced it was contributing $10.5 million to a project led by OmniaBio supporting commercial scale manufacturing of cell and gene therapies in Canada. To find out more, watch the announcement below.